What is the 13F Pro Quality Score for MDT?

13F Pro ranks Medtronic plc (MDT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View MDT's current score at https://13fpro.ai/research/MDT (free sign-up required for the full ranking).

Which hedge funds own the most MDT stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of MDT include BlackRock,, VANGUARD CAPITAL MANAGEMENT, STATE STREET. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/MDT as soon as new 13F filings post.

Where does 13F Pro source MDT data?

All Medtronic plc fundamentals and ownership data come directly from SEC EDGAR. Medtronic plc files with the SEC under CIK 1613103. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is MDT in?

Medtronic plc (MDT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is MDT research updated on 13F Pro?

MDT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Medtronic plc(MDT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 1613103 MDT stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

MDT Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Medtronic plc (MDT), a Healthcare sector company. MDT is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q4 2026), Medtronic plc reports quarterly revenue of $9.8B, net income of $1.2B, an operating margin of 19.1%. Top institutional holders of MDT by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. MDT trades on the NYSE exchange and files with the SEC under CIK 1613103. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MDT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Medtronic plc directly from SEC EDGAR.

Revenue

Q4 2026

$9.8B

Net Income

Q4 2026

$1.2B

Free Cash Flow

Q4 2026

$2.1B

Operating Margin

Q4 2026

19.1%

ROIC

Q4 2026

2.5%

D/E Ratio

Q4 2026

0.57

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+8.4% YoY

$36.36BFY 2026

FY22 $31.69BFY23 $31.23BFY25 $33.54BFY26 $36.36B

Net Income

+3.0% YoY

$4.80BFY 2026

FY22 $5.04BFY23 $3.76BFY25 $4.66BFY26 $4.80B

Operating Income

+8.6% YoY

$6.47BFY 2026

FY22 $5.75BFY23 $5.49BFY25 $5.96BFY26 $6.47B

EPS (Diluted)

+3.3% YoY

$3.73FY 2026

FY22 $3.73FY23 $2.82FY25 $3.61FY26 $3.73

Total Assets

+1.5% YoY

$93.03BFY 2026

FY22 $90.98BFY23 $90.95BFY25 $91.68BFY26 $93.03B

Total Debt

-1.9% YoY

$27.96BFY 2026

FY22 $24.11BFY23 $24.36BFY25 $28.52BFY26 $27.96B

Op. Cash Flow

+4.1% YoY

$7.33BFY 2026

FY22 $7.35BFY23 $6.04BFY25 $7.04BFY26 $7.33B

Metric	FY 2026	FY 2025	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$36.36B +8.4%	$33.54B +7.4%	$31.23B -1.4%	$31.69B +5.2%	$30.12B +4.2%	$28.91B
Net Income	$4.80B +3.0%	$4.66B +24.1%	$3.76B -25.4%	$5.04B +39.7%	$3.61B -24.7%	$4.79B
Operating Income	$6.47B +8.6%	$5.96B +8.6%	$5.49B -4.6%	$5.75B +28.3%	$4.48B -6.4%	$4.79B
EPS (Diluted)	$3.73 +3.3%	$3.61 +28.0%	$2.82 -24.4%	$3.73 +40.2%	$2.66 -24.9%	$3.54
Total Assets	$93.03B +1.5%	$91.68B +0.8%	$90.95B -0.0%	$90.98B -2.3%	$93.08B +2.6%	$90.69B
Total Debt	$27.96B -1.9%	$28.52B +17.0%	$24.36B +1.0%	$24.11B -8.6%	$26.39B -13.4%	$30.47B
Operating Cash Flow	$7.33B +4.1%	$7.04B +16.6%	$6.04B -17.8%	$7.35B +17.7%	$6.24B -13.7%	$7.23B

AI Insight: MDT Financial Trends

Revenue growth accelerating to 10% YoY in Q2 2026, while operating margin expanded to 19.1% — highest in dataset — as debt declines.

• Revenue grew 10.0% YoY from Q2 2025 ($8,927M) to Q2 2026 ($9,807M), marking strongest quarterly growth in the period.

• Operating margin expanded to 19.1% in Q2 2026 versus 16.1% in Q2 2025, a 100bp improvement year-over-year.

• Total debt declined to $27,961M in Q2 2026 from peak of $29,100M in Q4 2025, reducing leverage headroom.

⚠ Operating cash flow deteriorated to $925M in Q4 2025 from $2,572M in Q1 2025, though rebounded to $2,573M in Q2 2026.

⚠ Net income volatility: Q3 2025 dipped to $1,040M before recovering to $1,374M in Q4 2025, signaling earnings instability.

AI Insight: MDT Ratio Trends

Medtronic swung back to strong profitability in Q2 2026 with operating margin of 19.1% and ROIC reaching 9.7%, highest in two years.

• Operating margin recovered to 19.1% in Q2 2026 from 16.2% in Q1 2026, reversing six-quarter volatility between 16–20%.

• ROIC expanded to 9.7% in Q2 2026, the highest level since Q1 2025 (8.7%), signaling improved capital efficiency.

• Debt-to-equity ratio remains stable near 0.57–0.60 across last four quarters, maintaining conservative leverage.

⚠ Q1 2026 showed significant margin contraction to 16.2% OpMargin and 7.6% ROIC, suggesting seasonal weakness or operational headwinds.

⚠ Net profit margin has oscillated between 11.8–15.6% over six quarters, indicating earnings volatility despite stable operating leverage.

Get alerted when MDT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Medtronic plc including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of MDT

BlackRock, Inc.
$9.8B113,182,567 sh
VANGUARD CAPITAL MANAGEMENT LLC
$7.2B83,333,833 sh
STATE STREET CORP
$5.4B61,741,014 sh
Capital Research Global Investors
$3.6B41,926,590 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$2.9B33,450,558 sh
MASSACHUSETTS FINANCIAL SERVICES CO /MA/
$2.7B21,437,599 sh
GEODE CAPITAL MANAGEMENT, LLC
$2.5B28,736,341 sh
BANK OF AMERICA CORP /DE/
$2.3B26,015,003 sh
MORGAN STANLEY
$1.8B20,717,029 sh
DEUTSCHE BANK AG\
$1.6B19,002,414 sh

Fund	Value	Shares
BlackRock, Inc.	$9.8B	113,182,567
VANGUARD CAPITAL MANAGEMENT LLC	$7.2B	83,333,833
STATE STREET CORP	$5.4B	61,741,014
Capital Research Global Investors	$3.6B	41,926,590
VANGUARD PORTFOLIO MANAGEMENT LLC	$2.9B	33,450,558
MASSACHUSETTS FINANCIAL SERVICES CO /MA/	$2.7B	21,437,599
GEODE CAPITAL MANAGEMENT, LLC	$2.5B	28,736,341
BANK OF AMERICA CORP /DE/	$2.3B	26,015,003
MORGAN STANLEY	$1.8B	20,717,029
DEUTSCHE BANK AG\	$1.6B	19,002,414

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put MDT on your watchlist

Track score changes the day Medtronic plc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is MDT a good stock to buy?

13F Pro's AI-powered analysis of Medtronic plc (MDT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MDT are available on the MDT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own MDT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MDT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Medtronic plc's investment landscape.